{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:39:34Z","timestamp":1792737574713,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Down syndrome regression disorder is a symptom cluster consisting of neuropsychiatric regression without cause. This study evaluated the incidence of neurodiagnostic abnormalities in individuals with Down syndrome regression disorder and determined if abnormalities are indicative of responses to therapeutic intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective, multi-center, case-control study was performed. Patients were required to have subacute onset and the presence of four of five symptom groups present (cognitive decline, expressive language, sleep derangement, loss of ability to perform activities of daily living, and\/or a new movement disorder) and no other explanation for symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Individuals with Down syndrome regression disorder were comparable to a cohort of individuals with only Down syndrome although had higher rates of autoimmune disease (<jats:italic>p<\/jats:italic> = 0.02, 95%CI 1.04\u20131.75). Neurodiagnostic abnormalities were found on EEG (<jats:italic>n<\/jats:italic> = 19, 26%), neuroimaging (<jats:italic>n<\/jats:italic> = 16, 22%), and CSF (<jats:italic>n<\/jats:italic> = 9, 17%). Pleocytosis was appreciated in five cases, elevated total protein in nine, elevated IgG index in seven, and oligoclonal bands in two. Testing within 2 years of symptom onset was more likely to have neurodiagnostic abnormalities (<jats:italic>p<\/jats:italic> = 0.01, 95%CI 1.64\u201337.06). In individuals with neurodiagnostic abnormalities, immunotherapy was nearly four times more likely to have a therapeutic effect than in those without neurodiagnostic abnormalities (OR 4.11, 95%CI 1.88\u20139.02). In those with normal neurodiagnostic studies (<jats:italic>n<\/jats:italic> = 43), IVIg was effective in 14 of 17 (82%) patients as well although other immunotherapies were uniformly ineffective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study reports the novel presence of neurodiagnostic testing abnormalities in individuals with Down syndrome regression disorder, providing credence to this symptom cluster potentially being of neurologic and\/or neuroimmunologic etiology.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s11689-022-09446-w","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:03:45Z","timestamp":1654250625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-8234","authenticated-orcid":false,"given":"Jonathan D.","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runi","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Pagarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellad","family":"Khoshnood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Rehmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Kammeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Y.","family":"Gombolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Conravey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"El-Dahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison L.","family":"Christy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Van Mater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Rafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen A.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"issue":"3","key":"9446_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41431-020-00748-y","volume":"29","author":"G de Graaf","year":"2021","unstructured":"de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in Europe. Eur J Hum Genet. 2021;29(3):402\u201310. https:\/\/doi.org\/10.1038\/s41431-020-00748-y published Online First: 2020\/11\/02.","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"9446_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1177\/0883073814554654","volume":"30","author":"G Worley","year":"2015","unstructured":"Worley G, Crissman BG, Cadogan E, et al. Down syndrome disintegrative disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with down syndrome. J Child Neurol. 2015;30(9):1147\u201352. https:\/\/doi.org\/10.1177\/0883073814554654 published Online First: 2014\/11\/05.","journal-title":"J Child Neurol"},{"key":"9446_CR3","doi-asserted-by":"publisher","unstructured":"Mircher C, Cieuta-Walti C, Marey I, et al. Acute regression in young people with Down syndrome. Brain Sci. 2017;7(6). https:\/\/doi.org\/10.3390\/brainsci7060057 published Online First: 2017\/05\/31.","DOI":"10.3390\/brainsci7060057"},{"issue":"4","key":"9446_CR4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41436-019-0706-8","volume":"22","author":"SL Santoro","year":"2020","unstructured":"Santoro SL, Cannon S, Capone G, et al. Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. Genet Med. 2020;22(4):767\u201376. https:\/\/doi.org\/10.1038\/s41436-019-0706-8 published Online First: 2019\/11\/27.","journal-title":"Genet Med"},{"key":"9446_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/ndt.S77307","volume":"11","author":"N Ghaziuddin","year":"2015","unstructured":"Ghaziuddin N, Nassiri A, Miles JH. Catatonia in Down syndrome; a treatable cause of regression. Neuropsychiatr Dis Treat. 2015;11:941\u20139. https:\/\/doi.org\/10.2147\/ndt.S77307 published Online First: 2015\/04\/22.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"9446_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/ndt.S32767","volume":"8","author":"K Akahoshi","year":"2012","unstructured":"Akahoshi K, Matsuda H, Funahashi M, et al. Acute neuropsychiatric disorders in adolescents and young adults with Down syndrome: Japanese case reports. Neuropsychiatr Dis Treat. 2012;8:339\u201345. https:\/\/doi.org\/10.2147\/ndt.S32767 published Online First: 2012\/08\/14.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Suppl 1","key":"9446_CR7","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/dbp.0000000000000401","volume":"38 Suppl 1","author":"DS Stein","year":"2017","unstructured":"Stein DS, Munir KM, Karweck AJ, et al. Developmental regression, depression, and psychosocial stress in an adolescent with Down syndrome. J Dev Behav Pediatr. 2017;38 Suppl 1(Suppl 1):S26\u2013s28. https:\/\/doi.org\/10.1097\/dbp.0000000000000401 published Online First: 2017\/02\/01.","journal-title":"J Dev Behav Pediatr"},{"key":"9446_CR8","doi-asserted-by":"publisher","unstructured":"Rosso M, Fremion E, Santoro SL, et al. Down syndrome disintegrative disorder: a clinical regression syndrome of increasing importance. Pediatrics. 2020;145(6). https:\/\/doi.org\/10.1542\/peds.2019-2939 published Online First: 2020\/05\/31.","DOI":"10.1542\/peds.2019-2939"},{"key":"9446_CR9","doi-asserted-by":"publisher","unstructured":"Gupta AR, Westphal A, Yang DYJ, et al. Neurogenetic analysis of childhood disintegrative disorder. Mol Autism 2017;8:19. doi: https:\/\/doi.org\/10.1186\/s13229-017-0133-0 [published Online First: 2017\/04\/11]","DOI":"10.1186\/s13229-017-0133-0"},{"issue":"12","key":"9446_CR10","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1177\/0883073812472391","volume":"28","author":"NP Rosman","year":"2013","unstructured":"Rosman NP, Bergia BM. Childhood disintegrative disorder: distinction from autistic disorder and predictors of outcome. J Child Neurol. 2013;28(12):1587\u201398. https:\/\/doi.org\/10.1177\/0883073812472391 published Online First: 2013\/01\/24.","journal-title":"J Child Neurol"},{"issue":"9","key":"9446_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/dmcn.13432","volume":"59","author":"O Scott","year":"2017","unstructured":"Scott O, Shi D, Andriashek D, et al. Clinical clues for autoimmunity and neuroinflammation in patients with autistic regression. Dev Med Child Neurol. 2017;59(9):947\u201351. https:\/\/doi.org\/10.1111\/dmcn.13432 published Online First: 2017\/04\/07.","journal-title":"Dev Med Child Neurol"},{"key":"9446_CR12","doi-asserted-by":"publisher","unstructured":"Mathieu ML, de Bellescize J, Till M, et al. Electrical status epilepticus in sleep, a constitutive feature of Christianson syndrome? Eur J Paediatr Neurol 2018;22(6):1124-1132. doi: https:\/\/doi.org\/10.1016\/j.ejpn.2018.07.004 [published Online First: 2018\/08\/22]","DOI":"10.1016\/j.ejpn.2018.07.004"},{"issue":"2","key":"9446_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/ajmg.b.32386","volume":"171b","author":"M Cederl\u00f6f","year":"2016","unstructured":"Cederl\u00f6f M, Pettersson E, Sariaslan A, et al. The association between childhood autistic traits and adolescent psychotic experiences is explained by general neuropsychiatric problems. Am J Med Genet B Neuropsychiatr Genet. 2016;171b(2):153\u20139. https:\/\/doi.org\/10.1002\/ajmg.b.32386 published Online First: 2015\/10\/16.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"9446_CR14","doi-asserted-by":"publisher","unstructured":"Bey AL, Gorman MP, Gallentine W, et al. Subacute neuropsychiatric syndrome in girls with SHANK3 mutations responds to immunomodulation. Pediatrics. 2020;145(2). https:\/\/doi.org\/10.1542\/peds.2019-1490 published Online First: 2020\/02\/06.","DOI":"10.1542\/peds.2019-1490"},{"issue":"7","key":"9446_CR15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/dmcn.14127","volume":"61","author":"KM Cardinale","year":"2019","unstructured":"Cardinale KM, Bocharnikov A, Hart SJ, et al. Immunotherapy in selected patients with Down syndrome disintegrative disorder. Dev Med Child Neurol. 2019;61(7):847\u201351. https:\/\/doi.org\/10.1111\/dmcn.14127 published Online First: 2018\/12\/15.","journal-title":"Dev Med Child Neurol"},{"key":"9446_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejpn.2021.01.001","volume":"30","author":"A Roliz","year":"2021","unstructured":"Roliz A, Shah Y, Morse A, et al. Clinical features of paediatric and adult autoimmune encephalitis: a multicenter sample. Eur J Paediatr Neurol. 2021;30:82\u20137. https:\/\/doi.org\/10.1016\/j.ejpn.2021.01.001 published Online First: 2021\/01\/19.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"9446_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","volume":"17","author":"S Jarius","year":"2020","unstructured":"Jarius S, Lechner C, Wendel EM, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: results from 108 lumbar punctures in 80 pediatric patients. J Neuroinflammation. 2020;17(1):262. https:\/\/doi.org\/10.1186\/s12974-020-01825-1 published Online First: 2020\/09\/05.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"9446_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1469-8749.2012.04443.x","volume":"55","author":"AJ Sinclair","year":"2013","unstructured":"Sinclair AJ, Wienholt L, Tantsis E, et al. Clinical association of intrathecal and mirrored oligoclonal bands in paediatric neurology. Dev Med Child Neurol. 2013;55(1):71\u20135. https:\/\/doi.org\/10.1111\/j.1469-8749.2012.04443.x published Online First: 2012\/10\/26.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"9446_CR19","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1212\/nxi.0000000000000010","volume":"1","author":"Y Hacohen","year":"2014","unstructured":"Hacohen Y, Singh R, Forsyth V, et al. CSF albumin and immunoglobulin analyses in childhood neurologic disorders. Neurol Neuroimmunol Neuroinflamm. 2014;1(1):e10. https:\/\/doi.org\/10.1212\/nxi.0000000000000010 published Online First: 2014\/10\/24.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"9446_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1469-8749.2008.03225.x","volume":"51","author":"RC Dale","year":"2009","unstructured":"Dale RC, Brilot F, Fagan E, et al. Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation. Dev Med Child Neurol. 2009;51(4):317\u201323. https:\/\/doi.org\/10.1111\/j.1469-8749.2008.03225.x published Online First: 2009\/02\/05.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"9446_CR21","doi-asserted-by":"publisher","first-page":"18291","DOI":"10.1038\/s41598-020-75500-z","volume":"10","author":"M Molero-Luis","year":"2020","unstructured":"Molero-Luis M, Casas-Alba D, Orellana G, et al. Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases. Sci Rep. 2020;10(1):18291. https:\/\/doi.org\/10.1038\/s41598-020-75500-z published Online First: 2020\/10\/28.","journal-title":"Sci Rep"},{"issue":"12","key":"9446_CR22","doi-asserted-by":"publisher","first-page":"e83237","DOI":"10.1371\/journal.pone.0083237","volume":"8","author":"M Molero-Luis","year":"2013","unstructured":"Molero-Luis M, Fern\u00e1ndez-Ure\u00f1a S, Jord\u00e1n I, et al. Cerebrospinal fluid neopterin analysis in neuropediatric patients: establishment of a new cut off-value for the identification of inflammatory-immune mediated processes. PLoS One. 2013;8(12):e83237. https:\/\/doi.org\/10.1371\/journal.pone.0083237 published Online First: 2013\/12\/25.","journal-title":"PLoS One"},{"issue":"6","key":"9446_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10875-020-00803-9","volume":"40","author":"XF Kong","year":"2020","unstructured":"Kong XF, Worley L, Rinchai D, et al. Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome. J Clin Immunol. 2020;40(6):807\u201319. https:\/\/doi.org\/10.1007\/s10875-020-00803-9 published Online First: 2020\/06\/24.","journal-title":"J Clin Immunol"},{"key":"9446_CR24","doi-asserted-by":"publisher","unstructured":"Sullivan KD, Lewis HC, Hill AA, et al. Trisomy 21 consistently activates the interferon response. Elife. 2016;5. https:\/\/doi.org\/10.7554\/eLife.16220 published Online First: 2016\/07\/30.","DOI":"10.7554\/eLife.16220"},{"issue":"7","key":"9446_CR25","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.celrep.2019.10.038","volume":"29","author":"KA Waugh","year":"2019","unstructured":"Waugh KA, Araya P, Pandey A, et al. Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in Down syndrome. Cell Rep. 2019;29(7):1893\u2013908.e4. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.038 published Online First: 2019\/11\/14.","journal-title":"Cell Rep"},{"issue":"48","key":"9446_CR26","doi-asserted-by":"publisher","first-page":"24231","DOI":"10.1073\/pnas.1908129116","volume":"116","author":"P Araya","year":"2019","unstructured":"Araya P, Waugh KA, Sullivan KD, et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proc Natl Acad Sci U S A. 2019;116(48):24231\u201341. https:\/\/doi.org\/10.1073\/pnas.1908129116 published Online First: 2019\/11\/09.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"9446_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10875-020-00755-0","volume":"40","author":"G Ottaviano","year":"2020","unstructured":"Ottaviano G, Gerosa J, Santini M, et al. A prevalent CXCR3(+) phenotype of circulating follicular helper T cells indicates humoral dysregulation in children with Down syndrome. J Clin Immunol. 2020;40(3):447\u201355. https:\/\/doi.org\/10.1007\/s10875-020-00755-0 published Online First: 2020\/01\/30.","journal-title":"J Clin Immunol"},{"key":"9446_CR28","doi-asserted-by":"publisher","first-page":"724436","DOI":"10.3389\/fimmu.2022.724436","volume":"13","author":"D Peeters","year":"2022","unstructured":"Peeters D, Pico-Knijnenburg I, Wieringa D, et al. AKT hyperphosphorylation and T cell exhaustion in Down syndrome. Front Immunol. 2022;13:724436. https:\/\/doi.org\/10.3389\/fimmu.2022.724436 published Online First: 2022\/03\/01.","journal-title":"Front Immunol"},{"issue":"3","key":"9446_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/eji.201445049","volume":"45","author":"R Carsetti","year":"2015","unstructured":"Carsetti R, Valentini D, Marcellini V, et al. Reduced numbers of switched memory B cells with high terminal differentiation potential in Down syndrome. Eur J Immunol. 2015;45(3):903\u201314. https:\/\/doi.org\/10.1002\/eji.201445049 published Online First: 2014\/12\/05.","journal-title":"Eur J Immunol"},{"issue":"6","key":"9446_CR30","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jaci.2014.07.015","volume":"134","author":"RHJ Verstegen","year":"2014","unstructured":"Verstegen RHJ, Driessen GJ, Bartol SJW, et al. Defective B-cell memory in patients with Down syndrome. J Allergy Clin Immunol. 2014;134(6):1346\u201353.e9. https:\/\/doi.org\/10.1016\/j.jaci.2014.07.015 published Online First: 2014\/08\/28.","journal-title":"J Allergy Clin Immunol"},{"key":"9446_CR31","doi-asserted-by":"publisher","first-page":"6937154","DOI":"10.1155\/2020\/6937154","volume":"2020","author":"L Tarani","year":"2020","unstructured":"Tarani L, Carito V, Ferraguti G, et al. Neuroinflammatory markers in the serum of prepubertal children with Down syndrome. J Immunol Res. 2020;2020:6937154. https:\/\/doi.org\/10.1155\/2020\/6937154 published Online First: 2020\/04\/14.","journal-title":"J Immunol Res"},{"key":"9446_CR32","doi-asserted-by":"publisher","first-page":"621637","DOI":"10.3389\/fneur.2021.621637","volume":"12","author":"SJ Hart","year":"2021","unstructured":"Hart SJ, Worley G, Kishnani PS, et al. Case report: improvement following immunotherapy in an individual with seronegative Down syndrome disintegrative disorder. Front Neurol. 2021;12:621637. https:\/\/doi.org\/10.3389\/fneur.2021.621637 published Online First: 2021\/04\/13.","journal-title":"Front Neurol"},{"issue":"2","key":"9446_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3988\/jcn.2021.17.2.300","volume":"17","author":"S Lee","year":"2021","unstructured":"Lee S, Kim HD, Lee JS, et al. Clinical features and treatment outcomes of seronegative pediatric autoimmune encephalitis. J Clin Neurol. 2021;17(2):300\u20136. https:\/\/doi.org\/10.3988\/jcn.2021.17.2.300 published Online First: 2021\/04\/10.","journal-title":"J Clin Neurol"},{"key":"9446_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pediatrneurol.2020.11.014","volume":"116","author":"ME McGetrick","year":"2021","unstructured":"McGetrick ME, Varughese NA, Miles DK, et al. Clinical features, treatment strategies, and outcomes in hospitalized children with immune-mediated encephalopathies. Pediatr Neurol. 2021;116:20\u20136. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.11.014 published Online First: 2021\/01\/04.","journal-title":"Pediatr Neurol"},{"key":"9446_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejpn.2020.10.001","volume":"29","author":"Y Shim","year":"2020","unstructured":"Shim Y, Kim SY, Kim H, et al. Clinical outcomes of pediatric anti-NMDA receptor encephalitis. Eur J Paediatr Neurol. 2020;29:87\u201391. https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.001 published Online First: 2020\/10\/14.","journal-title":"Eur J Paediatr Neurol"},{"key":"9446_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Wendel EM, Lechner C, et al. E.U. Paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:41\u201353. https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.005 published Online First: 2020\/11\/13.","journal-title":"Eur J Paediatr Neurol"},{"key":"9446_CR37","doi-asserted-by":"publisher","unstructured":"Mizia-Malarz A, Stolpa W, Sobol-Milejska G. The treatment of opsoclonus-myoclonus syndrome secondary to neuroblastic tumours-single-centre experience and literature review. Medicina (Kaunas). 2020;56(8). https:\/\/doi.org\/10.3390\/medicina56080412 published Online First: 2020\/08\/23.","DOI":"10.3390\/medicina56080412"},{"issue":"10","key":"9446_CR38","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","volume":"383","author":"A Vanderver","year":"2020","unstructured":"Vanderver A, Adang L, Gavazzi F, et al. Janus kinase inhibition in the Aicardi-Gouti\u00e8res syndrome. N Engl J Med. 2020;383(10):986\u20139. https:\/\/doi.org\/10.1056\/NEJMc2001362 published Online First: 2020\/09\/03.","journal-title":"N Engl J Med"},{"issue":"1","key":"9446_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s11689-019-9306-9","volume":"12","author":"CM Startin","year":"2020","unstructured":"Startin CM, D\u2019Souza H, Ball G, et al. Health comorbidities and cognitive abilities across the lifespan in Down syndrome. J Neurodev Disord. 2020;12(1):4. https:\/\/doi.org\/10.1186\/s11689-019-9306-9 published Online First: 2020\/01\/25.","journal-title":"J Neurodev Disord"},{"key":"9446_CR40","doi-asserted-by":"publisher","unstructured":"Thom RP, Palumbo ML, Thompson C, et al. Selective serotonin reuptake inhibitors for the treatment of depression in adults with Down syndrome: a preliminary retrospective chart review study. Brain Sci. 2021;11(9). https:\/\/doi.org\/10.3390\/brainsci11091216 published Online First: 2021\/09\/29.","DOI":"10.3390\/brainsci11091216"},{"issue":"17","key":"9446_CR41","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1080\/14656566.2018.1529167","volume":"19","author":"ML Palumbo","year":"2018","unstructured":"Palumbo ML, McDougle CJ. Pharmacotherapy of Down syndrome. Expert Opin Pharmacother. 2018;19(17):1875\u201389. https:\/\/doi.org\/10.1080\/14656566.2018.1529167 published Online First: 2018\/09\/28.","journal-title":"Expert Opin Pharmacother"},{"key":"9446_CR42","doi-asserted-by":"publisher","first-page":"100305","DOI":"10.1016\/j.ynstr.2021.100305","volume":"14","author":"F Poumeaud","year":"2021","unstructured":"Poumeaud F, Mircher C, Smith PJ, et al. Deciphering the links between psychological stress, depression, and neurocognitive decline in patients with Down syndrome. Neurobiol Stress. 2021;14:100305. https:\/\/doi.org\/10.1016\/j.ynstr.2021.100305 published Online First: 2021\/02\/23.","journal-title":"Neurobiol Stress"},{"key":"9446_CR43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.neulet.2016.11.023","volume":"636","author":"P Zis","year":"2017","unstructured":"Zis P, Strydom A, Buckley D, et al. Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity. Neurosci Lett. 2017;636:254\u20137. https:\/\/doi.org\/10.1016\/j.neulet.2016.11.023 published Online First: 2016\/11\/17.","journal-title":"Neurosci Lett"},{"key":"9446_CR44","doi-asserted-by":"publisher","first-page":"577285","DOI":"10.1016\/j.jneuroim.2020.577285","volume":"345","author":"J H\u00e9bert","year":"2020","unstructured":"H\u00e9bert J, Gros P, Lapointe S, et al. Searching for autoimmune encephalitis: beware of normal CSF. J Neuroimmunol. 2020;345:577285. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577285 published Online First: 2020\/06\/21.","journal-title":"J Neuroimmunol"},{"key":"9446_CR45","doi-asserted-by":"publisher","first-page":"646940","DOI":"10.3389\/fimmu.2021.646940","volume":"12","author":"T Zrzavy","year":"2021","unstructured":"Zrzavy T, H\u00f6ftberger R, Wimmer I, et al. Longitudinal CSF findings in autoimmune encephalitis-a monocentric cohort study. Front Immunol. 2021;12:646940. https:\/\/doi.org\/10.3389\/fimmu.2021.646940 published Online First: 2021\/04\/09.","journal-title":"Front Immunol"},{"key":"9446_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2015.10.016","volume":"55","author":"DV Albert","year":"2016","unstructured":"Albert DV, Pluto CP, Weber A, et al. Utility of neurodiagnostic studies in the diagnosis of autoimmune encephalitis in children. Pediatr Neurol. 2016;55:37\u201345. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2015.10.016 published Online First: 2016\/01\/05.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"9446_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391\u2013404. https:\/\/doi.org\/10.1016\/s1474-4422(15)00401-9 published Online First: 2016\/02\/26.","journal-title":"Lancet Neurol"},{"key":"9446_CR48","doi-asserted-by":"publisher","unstructured":"Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020;7(2). https:\/\/doi.org\/10.1212\/nxi.0000000000000663 published Online First: 2020\/01\/19.","DOI":"10.1212\/nxi.0000000000000663"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-022-09446-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-022-09446-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-022-09446-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:03:56Z","timestamp":1654250636000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-022-09446-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9446"],"URL":"https:\/\/doi.org\/10.1186\/s11689-022-09446-w","relation":{},"ISSN":["1866-1947","1866-1955"],"issn-type":[{"value":"1866-1947","type":"print"},{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was IRB-approved. Consent and assent were waived as it was retrospective in nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}